An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%. The findings, published today in ...

The approval of benralizumab (Fasenra) is supported by evidence from the phase 3 TATE study. The FDA has approved benralizumab (Fasenra) for children aged 6 to 11 years with severe eosinophilic asthma ...

Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on ...

Treatment with benralizumab significantly delayed the time to first worsening or flare of symptoms in hypereosinophilic syndrome (HES), based on new data from the NATRON study presented at the ...

LONDON (Reuters) - AstraZeneca hopes to convince doctors its experimental injection for severe asthma has an edge over two approved rivals after clinical trials data on Monday showed it worked well ...